Jaguar Health, Inc.

NasdaqCM:JAGX Rapporto sulle azioni

Cap. di mercato: US$10.8m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Jaguar Health Gestione

Gestione criteri di controllo 4/4

Jaguar Health's Il CEO è Lisa Conte, nominato in Jun2013, e ha un mandato di 11.17 anni. la retribuzione annua totale è $ 815.85K, composta da 70.6% di stipendio e 29.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.001% delle azioni della società, per un valore di $ 154.92. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.7 anni e 6.4 anni.

Informazioni chiave

Lisa Conte

Amministratore delegato

US$815.9k

Compenso totale

Percentuale dello stipendio del CEO70.6%
Mandato del CEO11.2yrs
Proprietà del CEO0.001%
Durata media del management3.7yrs
Durata media del Consiglio di amministrazione6.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%

Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth

Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%

Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump

Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt

Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment

Oct 17

Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront

Aug 25

Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule

Aug 19

Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea

Aug 09

Jaguar stock rises on license deal with SynWorld for Canalevia in China

Jun 29

Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory

Mar 07

Jaguar Health shares jumps 13% after pricing $15M direct offering

Jan 13

Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients

Jan 11

Jaguar Health leaps higher in new year

Jan 05

Jaguar Health inks second Mytesi royalties agreement for $6M

Dec 23

Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Dec 02
Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?

Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%

Nov 30

Jaguar Health EPS misses by $0.10, misses on revenue

Nov 16

Jaguar Health receives positive Nasdaq listing determination

Oct 29

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Lisa Conte rispetto agli utili di Jaguar Health?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$36m

Mar 31 2024n/an/a

-US$38m

Dec 31 2023US$816kUS$576k

-US$41m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$44m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$1mUS$603k

-US$47m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$3mUS$527k

-US$53m

Sep 30 2021n/an/a

-US$50m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020US$1mUS$500k

-US$39m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$39m

Mar 31 2020n/an/a

-US$45m

Dec 31 2019US$1mUS$500k

-US$45m

Sep 30 2019n/an/a

-US$48m

Jun 30 2019n/an/a

-US$43m

Mar 31 2019n/an/a

-US$34m

Dec 31 2018US$1mUS$480k

-US$32m

Sep 30 2018n/an/a

-US$41m

Jun 30 2018n/an/a

-US$30m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$643kUS$440k

-US$22m

Compensazione vs Mercato: La retribuzione totale di Lisa ($USD 815.85K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di Lisa è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Lisa Conte (65 yo)

11.2yrs

Mandato

US$815,854

Compensazione

Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Lisa Conte
Founder11.2yrsUS$815.85k0.0013%
$ 142.7
Pravin Chaturvedi
Chief Scientific Officer & Chair of Scientific Advisory Board2.4yrsUS$627.13k0.00039%
$ 42.2
Jonathan Wolin
Chief of Staff5.8yrsUS$562.79k0.00037%
$ 40.0
Steven King
Chief of Sustainable Supply9.9yrsUS$491.54k0.00031%
$ 33.5
Carol Lizak
Chief Financial Officer4.4yrsNessun dato0.00018%
$ 19.5
Peter Hodge
Senior Director of Investor Relationsno dataNessun datoNessun dato
Karen Brunke
Executive VP of Corporate & Business Development2.9yrsNessun datoNessun dato
David Sesin
Chief Manufacturing Officerno dataNessun datoNessun dato
Ian Wendt
Chief Commercial Officer3.7yrsUS$557.90kNessun dato
Massimo Radaelli
President of Jaguar Internationalless than a yearNessun datoNessun dato
Catherine Collis
Senior Vice President of Growth Strategyless than a yearNessun datoNessun dato
Darlene Horton
Chief Medical Officerno dataNessun datoNessun dato

3.7yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di JAGX è considerato esperto (durata media dell'incarico 3.7 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Lisa Conte
Founder11.2yrsUS$815.85k0.0013%
$ 142.7
Pravin Chaturvedi
Chief Scientific Officer & Chair of Scientific Advisory Board7.3yrsUS$627.13k0.00039%
$ 42.2
James Bochnowski
Independent Chairman10.5yrsUS$140.98k0.00041%
$ 44.3
John Micek
Independent Director8.3yrsUS$101.68k0.00024%
$ 25.9
Anula Jayasuriya
Independent Director2.1yrsUS$77.61k0.00031%
$ 33.5
Jonathan Siegel
Independent Director6.4yrsUS$104.18k0.00026%
$ 28.1
Sandra Swain
Member of Scientific Advisory Board1.6yrsNessun datoNessun dato
Kelly Shanahan
Scientific Advisory Board1.4yrsNessun datoNessun dato
Stacey Tinianov
Member of Scientific Advisory Board1.3yrsNessun datoNessun dato

6.4yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di JAGX sono considerati esperti (durata media dell'incarico 6.4 anni).